CLAIM AMENDMENTS

1. (original) Liquid crystal gel for use in the manufacture of transdermal pharmaceutical compositions and healing cosmetics characterized in that the gel containing polyoxyethyleneglyceryl-trioleate, propylene-glycol, isopropyl myristate and a hyaluronic acid salt or complex.

2. (original) The liquid crystal gel for use in the manufacture of transdermal pharmaceutical compositions and healing cosmetics according to claim 1 characterized in that the amount of polyoxyethylene-glyceryl-trioleate in the gel varies between 26.7 and 40% (w/w) of the total weight of the gel.

3. (canceled)

4. (canceled)

5. (original) The liquid crystal gel for use in the manufacture of transdermal pharmaceutical compositions and healing cosmetics according to any of claims 1-4 characterized in that the amount of propylene-glycol added to the gel varies between 13.3 and 20% (w/w) of the total weight of the gel.

6. (canceled)

7. (canceled)

8. (original) The liquid crystal gel for use in the manufacture of transdermal pharmaceutical compositions and healing cosmetics according to any of claims 1-7 characterized in that the ratio of polyoxyethylene-glyceryl-trioleate and propylene-glycol is 2 : 1.

9. (original) The liquid crystal gel for use in the manufacture of transdermal pharmaceutical compositions and healing cosmetics according to any of claims 1-8 characterized in that the amount of isopropyl-myristate added to the gel varies between 5 and 35% (w/w) of the total weight of the gel.

10. (canceled)

11. (canceled)

12. (original) The liquid crystal gels for use in the manufacture of transdermal pharmaceutical compositions and healing cosmetics according to any of claims 1-11 characterized in that sodium-hyaluronate is applied as hyaluronic acid salt.

13. (original) The liquid crystal gels for use in the manufacture of transdermal pharmaceutical compositions and healing

cosmetics according to any of claims 1-11 characterized in that hyaluronic acid zinc complex is applied as hyaluronic acid complex.

14. (original) The liquid crystal gel for use in the manufacture of transdermal pharmaceutical compositions and healing cosmetics according to any of claims 12-13 characterized in that the amount of sodium-hyaluronate or hyaluronic acid zinc complex in the gel varies between 0.01 and 2% (w/w) of the total weight of the gel.

15. (canceled)

16. (canceled)

17. (original) Transdermal pharmaceutical composition characterized in that the composition consists of an estrogen and progestin component as well as a liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, propylene-glycol, isopropyl myristate and a hyaluronic acid salt or complex.

18. (original) The pharmaceutical composition according to claim 17 characterized in that the estrogen component is estradiol.

19. (canceled)

20. (original) The pharmaceutical composition according to any of claims 17-19 characterized in that the progestin component is gestodene.

21. (canceled)

22. (original) The pharmaceutical composition according to any of claims 17-19 characterized in that the progestin component is etonogestrel.

23. (canceled)

24. (original) The pharmaceutical composition according to any of claims 17-19 characterized in that the progestin component is levonorgestrel.

25. (canceled)

26. (currently amended) ~~Method of treatment for~~ A method of treating a patient for moderate to severe vasomotor symptoms, as well as hot flashes, nocturnal sweating, and palpitation due to post-menopausal estrogen deficiency, which comprises the step of transdermally administering to the skin of the patient ~~transdermal hormone replacement therapy characterized in that~~ a therapeutically effective amount of a pharmaceutical composition for hormone replacement which consists essentially of an estrogen and a

progestin component as well as a liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, propylene-glycol, isopropyl myristate and a hyaluronic acid salt or complex ~~is applied onto the surface to be treated~~.

27. (Canceled)

28. (original) Transdermal pharmaceutical composition characterized in that the composition consists of one or more active agent components as well as a liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, propylene-glycol, isopropyl myristate and a hyaluronic acid salt or complex.

29. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is ondansetron.

30. (canceled)

31. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is terbinafine.

32. (canceled)

33. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is fluconazole.

34. (canceled)

35. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is metronidazole.

36. (canceled)

37. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is fentanyl.

38. (canceled)

39. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is nandrolone decanoate.

40. (canceled)

41. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is nestorone.

42. (canceled)

43. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is norethisterone.

44. (canceled)

45. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is eperisone.

46. (canceled)

47. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is tolperisone.

48. (canceled)

49. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is vinpocetine.

50. (canceled)

51. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is ketamine.

52. (canceled)

53. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is vincristine.

54. (canceled)

55. (original) The pharmaceutical composition according to claim 28 characterized in that the active agent component is vinblastine.

56. (canceled)

57. (canceled)

58. (canceled)

59. (canceled)

60. (canceled)

61. (canceled)

62. (canceled)

63. (canceled)

64. (canceled)

65. (canceled)

66. (canceled)

67. (canceled)

68. (canceled)

69. (canceled)

70. (canceled)